Each component of the metabolic syndrome is not necessarily clustered coincidentally. Thus, subjects who have obesity, dyslipidemia or impaired glucose tolerance may be at high risk for the development of hypertension. We studied the predictive value of the following for the development of hypertension: obesity (body mass index ≥25.0 kg/m2), dyslipidemia (high-density lipoprotein-cholesterol <40 mg/dL, triglyceride ≥150 mg/dL, or use of anti-dyslipidemic drugs), high normal blood pressure (130 mmHg ≤ systolic <140 mmHg, or 85 mmHg ≤ diastolic <90 mmHg), and impaired glucose tolerance (fasting plasma glucose ≥110 mg/dL or use of anti-diabetic agents). This observational study included 5,785 subjects without hypertension recruited from participants in our health checkup program. They were followed up for 1,097±365 d, with the endpoint being the development of hypertension. During the follow-up, hypertension developed in 1,168 subjects (74.1 per 1,000 person-years). The incidence of hypertension was higher in subjects who had obesity (106.2 vs. 67.8), dyslipidemia (96.1 vs. 69.0), high normal blood pressure (166.0 vs. 40.1), or impaired glucose tolerance (130.5 vs. 65.3 per 1,000 person-years) than in those without these disorders at baseline. The risk of hypertension was increased as the number of metabolic disorders in an individual increased. Multiple regression analysis indicated that obesity, high normal blood pressure, and impaired glucose tolerance remained independent predictors of the onset of hypertension. Thus, the presence of individual components of the metabolic syndrome predicts the development of hypertension. Prediction of the development of hypertension may lead to effective prevention of both hypertension and resulting cardiovascular diseases.
Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 ( Suppl): S1–S105.
Burt VL, Whelton P, Roccella EJ, et al: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–313.
Vasan RS, Beiser A, Seshadri SR, et al: Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002; 287: 1003–1010.
Ong KL, Cheung BM, Man YB, Lau CP, Lam KS : Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007; 49: 69–75.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143–3421.
Ford ES, Giles WH, Mokdad AH : Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444–2449.
Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, DECODE Study Group: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066–1076.
Tamaki S, Nakamura Y, Tabara Y, et al: Relationship between metabolic syndrome and Trp64Arg polymorphism of the β3-adrenergic receptor gene in a general sample: the Shigaraki Study. Hypertens Res 2006; 29: 891–896.
Mancia G, Bombelli M, Corrao G, et al: Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 40–47.
Ford ES : Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769–1778.
Galassi A, Reynolds K, He J : Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812–819.
Takeuchi H, Saitoh S, Takagi S, et al: Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program–Adult Treatment Panel III to Japanese men—the Tanno and Sobetsu Study. Hypertens Res 2005; 28: 203–208.
Koji Y, Tomiyama H, Yamada J, et al: Relationship between Arterial Stiffness and the Risk of Coronary Artery Disease in Subjects with and without Metabolic Syndrome. Hypertens Res 2007; 30: 243–247.
Nishina M, Kikuchi T, Yamazaki H, Kameda K, Hiura M, Uchiyama M : Relationship among systolic blood pressure, serum insulin and leptin, and visceral fat accumulation in obese children. Hypertens Res 2003; 26: 281–288.
Ogawa Y, Kikuchi T, Nagasaki K, Hiura M, Tanaka Y, Uchiyama M : Usefulness of serum adiponectin level as a diagnostic marker of metabolic syndrome in obese Japanese children. Hypertens Res 2005; 28: 51–57.
Matsuzawa Y : The metabolic syndrome and adipocytokines. FEBS Lett 2006; 580: 2917–2921.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K : Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784–1792.
Chiba Y, Saitoh S, Takagi S, et al: Relationship between visceral fat and cardiovascular disease risk factors: the Tanno and Sobetsu study. Hypertens Res 2007; 30: 229–236.
Eguchi M, Tsuchihashi K, Saitoh S, et al: Visceral obesity in Japanese patients with metabolic syndrome: reappraisal of diagnostic criteria by CT scan. Hypertens Res 2007; 30: 315–323.
Kanai H, Tokunaga K, Fujioka S, Yamashita S, Kameda-Takemura KK, Matsuzawa Y : Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 1996; 27: 125–129.
The Trials of Hypertension Prevention Collaborative Research Group: Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997; 157: 657–667.
Julius S, Nesbitt SD, Egan BM, et al, Trial of Preventing Hypertension (TROPHY) Study Investigators: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685–1697.
Sesso HD, Wang L, Buring JE, Ridker PM, Gaziano JM : Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 2007; 49: 304–310.
Wang TJ, Gona P, Larson MG, et al: Multiple biomarkers and the risk of incident hypertension. Hypertension 2007; 49: 432–438.
Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C : The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 2005; 183: 308–315.
Shoelson SE, Lee J, Goldfine AB : Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793–1801.
Saijo Y, Yoshioka E, Fukui T, Kawaharada M, Kishi R : Metabolic syndrome, C-reactive protein and increased arterial stiffness in Japanese subjects. Hypertens Res 2006; 29: 589–596.
Dohi Y, Takase H, Sato K, Ueda R : Association among C-reactive protein, oxidative stress, and traditional risk factors in healthy Japanese subjects. Int J Cardiol 2007; 115: 63–66.
Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A : High-normal blood pressure progression to hypertension in the Framingham Heart Study. Hypertension 1991; 17: 22–27.
Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D : Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682–1686.
Vasan RS, Larson MG, Leip EP, et al: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–1297.
Stamler J, Stamler R, Neaton JD, et al: Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999; 282: 2012–2018.
Kriketos AD, Robertson RM, Sharp TA, et al: Role of weight loss and polyunsaturated fatty acids in improving metabolic fitness in moderately obese, moderately hypertensive subjects. J Hypertens 2001; 19: 1745–1754.
Whelton PK, He J, Appel LJ, et al, National High Blood Pressure Education Program Coordinating Committee: Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 2002; 288: 1882–1888.
Niskanen L, Laaksonen DE, Nyyssonen K, et al: Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004; 44: 859–865.
Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F : Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005; 28: 2823–2831.
Elmer PJ, Obarzanek E, Vollmer WM, et al, PREMIER Collaborative Research Group: Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006; 144: 485–495.
About this article
Cite this article
Takase, H., Dohi, Y., Toriyama, T. et al. Metabolic Disorders Predict Development of Hypertension in Normotensive Japanese Subjects. Hypertens Res 31, 665–671 (2008). https://doi.org/10.1291/hypres.31.665
- body mass index
- high-density lipoprotein cholesterol
- impaired glucose tolerance
- metabolic syndrome
Body mass index, abdominal fatness, and hypertension incidence: a dose-response meta-analysis of prospective studies
Journal of Human Hypertension (2018)
The associations of metabolic syndrome with incident hypertension, type 2 diabetes mellitus and chronic kidney disease: a cohort study
The influence of insulin resistance and obesity on left atrial size in Japanese hypertensive patients
Hypertension Research (2009)